Core Insights - Alkermes plc is a biopharmaceutical company focused on innovative medicines for central nervous system disorders and oncology, with a strong product pipeline and strategic initiatives for future growth [1] - The company operates in a competitive industry alongside major players like Biogen and Amgen, but its unique focus and robust financial health differentiate it [1] Recent Performance - Alkermes has shown a notable monthly gain of approximately 8.89%, indicating a strong upward trend [2][6] - However, the stock experienced a slight decline of about 2.36% in the last 10 days, which may present a strategic entry point for investors [2][6] Growth Potential - The stock has significant growth potential, with an estimated increase of approximately 44.75%, suggesting that it is currently undervalued [3][6] - The target price for Alkermes is set at $43.80, aligning with its growth potential and providing a clear upside for investors [3] Financial Health - Alkermes has a perfect Piotroski Score of 9, indicating robust financial health, efficient operations, and potential for future growth [4] - A score of 9 reflects the company's solid financial foundation, making it an attractive investment option [4] Investment Opportunity - Overall, Alkermes presents a compelling investment opportunity due to its recent stock price dip, strong financial metrics, and growth potential [5] - The significant upside associated with the target price of $43.80 makes it an appealing option for investors [5]

Core Points - Royalty Pharma's board of directors has approved a dividend of $0.22 per Class A ordinary share for the fourth quarter of 2025 [1] - The dividend payment date is set for December 10, 2025, with a record date of November 14, 2025 [1] Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a significant funder of innovation in the biopharmaceutical industry [2] - The company collaborates with various entities, including academic institutions, research hospitals, non-profits, small and mid-cap biotechnology companies, and leading global pharmaceutical companies [2] - Royalty Pharma's portfolio includes royalties from over 35 commercial products and 17 development-stage product candidates, entitling it to payments based on the top-line sales of leading therapies [2]

[FORM 8-K Filing Information](index=1&type=section&id=FORM%208-K%20Filing%20Information) Details Biogen Inc.'s registrant information, common stock registration, and the report's filing date [Registrant Information](index=1&type=section&id=Registrant%20Information) This section identifies Biogen Inc. as the registrant, detailing its incorporation state, commission file number, IRS employer ID, principal executive offices, and telephone number - Registrant: **Biogen Inc.**, incorporated in Delaware[2](index=2&type=chunk) - Date of Report: **October 14, 2025**[2](index=2&type=chunk) [Securities Information](index=1&type=section&id=Securities%20Information) The company's common stock is registered on The Nasdaq Global Select Market under the trading symbol BIIB Securities Registered | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $0.0005 par value | BIIB | The Nasdaq Global Select Market | - Biogen Inc. is not an emerging growth company[4](index=4&type=chunk) [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Presents preliminary Q3 2025 financial estimates, R&D expense definitions, and forward-looking statement disclosures [Estimated Financial Impact for Q3 2025](index=2&type=section&id=Estimated%20Financial%20Impact%20for%20Q3%202025) Biogen Inc. anticipates an approximate $2 million pre-tax charge for acquired in-process research and development, upfront and milestone expense in Q3 2025, which is expected to reduce GAAP and non-GAAP net income per diluted share by approximately $0.01 Estimated Q3 2025 Financial Impact | Metric | Estimated Impact (USD) | | :------------------------------------------------------------------ | :--------------------- | | Acquired in-process R&D, upfront and milestone expense (pre-tax) | ~$2 million | | Impact on GAAP and non-GAAP net income per diluted share | ~($0.01) per share | [Definition and Presentation of Acquired In-Process R&D Expense](index=2&type=section&id=Definition%20and%20Presentation%20of%20Acquired%20In-Process%20R%26D%20Expense) Starting Q1 2025, Biogen began presenting acquired in-process research and development, upfront and milestone expense as a separate line item, which the company does not forecast due to uncertainty - Acquired in-process R&D, upfront, and milestone expense began separate line item presentation in **Q1 2025**[6](index=6&type=chunk) - Expense encompasses costs from collaboration and license agreements, including upfront/milestone payments and premiums on equity securities/asset acquisitions of acquired in-process R&D[6](index=6&type=chunk) - Biogen does not forecast these expenses due to their uncertain future occurrence, magnitude, and timing[6](index=6&type=chunk) [Preliminary Nature of Results](index=2&type=section&id=Preliminary%20Nature%20of%20Results) The financial results for the quarter ended September 30, 2025, are preliminary and subject to finalization, with no assurance that final results will not differ from these unaudited estimates - Q3 2025 results are preliminary and subject to financial statement closing procedures[7](index=7&type=chunk) - Final results may differ from preliminary unaudited estimates[7](index=7&type=chunk) [Note Regarding Forward-Looking Statements](index=2&type=section&id=Note%20Regarding%20Forward-Looking%20Statements) This report contains forward-looking statements, made under the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties, and are not publicly updated - Forward-looking statements are subject to substantial risks and uncertainties, potentially causing actual results to differ materially[8](index=8&type=chunk)[9](index=9&type=chunk) - Statements are based on management's current beliefs, assumptions, and available information[9](index=9&type=chunk) - Investors are cautioned against undue reliance; the company does not undertake to publicly update these statements[10](index=10&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) Lists the exhibits furnished with the Form 8-K, including the interactive data file [Exhibits](index=2&type=section&id=Exhibits) This section lists the exhibits furnished as part of the Current Report on Form 8-K, specifically Exhibit 104, which is the Cover Page Interactive Data File Exhibits Furnished | Exhibit No. | Description | | :---------- | :------------------------------------------------ | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | [Signatures](index=3&type=section&id=Signatures) Confirms the official signing of the report by Biogen Inc.'s Secretary on October 14, 2025 [Report Signature](index=3&type=section&id=Report%20Signature) The report was duly signed on behalf of Biogen Inc. by Wendell Taylor, Secretary, on October 14, 2025, in accordance with the requirements of the Securities Exchange Act of 1934 - Report signed by **Wendell Taylor**, Secretary, on behalf of Biogen Inc[15](index=15&type=chunk) - Date of signature: **October 14, 2025**[15](index=15&type=chunk)

Core Insights - LEQEMBI IQLIK™, a subcutaneous autoinjector formulation of lecanemab for Alzheimer's disease treatment, has been recognized by TIME as one of the "Best Inventions of 2025" in the Medical and Healthcare category [1][2] Product Overview - LEQEMBI IQLIK is the first anti-amyloid treatment allowing at-home injections, enabling patients to continue treatment after an initial 18-month period [3] - The treatment was approved in the U.S. in August 2025 and launched on October 6, 2025 [3] - It offers a quick administration time of approximately 15 seconds, reducing the need for infusion center visits and associated healthcare resources [3] Clinical Background - LEQEMBI is the first approved anti-amyloid treatment shown to slow cognitive and functional decline in early Alzheimer's disease [4] - It has been approved in 50 countries and is under regulatory review in 10 additional countries [4][28] - The treatment's efficacy was demonstrated in the Clarity AD clinical trial, where it reduced clinical decline on the Clinical Dementia Rating Sum of Boxes (CDR-SB) by 27% at 18 months compared to placebo [29] Safety and Efficacy - The safety profile of LEQEMBI IQLIK is similar to that of the intravenous formulation, with a lower incidence of systemic reactions [31] - Common adverse reactions include infusion-related reactions (26% with LEQEMBI vs. 7% with placebo), ARIA-H (14% vs. 8%), and ARIA-E (13% vs. 2%) [25] - The incidence of amyloid-related imaging abnormalities (ARIA) was observed at 21% for LEQEMBI compared to 9% for placebo [11] Collaboration and Development - Eisai leads the global development and regulatory submissions for LEQEMBI, with Biogen co-commercializing and co-promoting the product [5][33] - The collaboration between Eisai and BioArctic has been ongoing since 2005, focusing on the development of Alzheimer's treatments [34]

Core Insights - Biogen's key multiple sclerosis (MS) drugs, including Tecfidera and Tysabri, along with the spinal muscular atrophy (SMA) treatment Spinraza, are experiencing declining sales due to increased competition, impacting overall revenue growth [1][3][10] Sales Performance - Sales of Tecfidera are declining due to the launch of multiple generic versions in North America, Brazil, and certain European countries [3] - Tysabri's sales are also declining as a result of heightened competition in the U.S. and the introduction of biosimilars in Europe, with a U.S. biosimilar expected by Q4 2025 [3][4] - Spinraza's revenues are anticipated to be lower in the second half of the year due to unfavorable shipment timing and competition from Novartis' Zolgensma and Roche's Evrysdi [5] New Drug Developments - Biogen's collaboration with Eisai on Leqembi for Alzheimer's disease shows potential for long-term growth, with sequential sales improvements noted over the past four quarters [6][10] - Leqembi has been launched in multiple countries and is expected to generate significant sales due to the unmet need in Alzheimer's treatment [7] - Skyclarys is witnessing strong demand trends, particularly in the U.S. and EU, with ex-U.S. sales projected to become a more significant growth driver in 2025 [9] Financial Outlook - Biogen's total revenues rose by 7% in the first half of 2025, driven by new drug sales, although the overall revenue for 2025 is projected to remain flat compared to 2024 [11][12] - The contribution from new drugs is increasing, but it is not yet sufficient to offset the declining revenues from MS drugs and Spinraza [12] Valuation and Estimates - Biogen's stock has declined by 2.2% this year, contrasting with an 8.7% increase in the industry [13] - The company's shares are trading at a forward price/earnings ratio of 9.49, lower than the industry average of 15.88 and its own 5-year mean of 13.55 [15] - The Zacks Consensus Estimate for 2025 earnings has increased from $14.87 to $15.68 per share over the past 90 days [16]

Core Insights - Zorevunersen shows potential as a disease-modifying treatment for Dravet syndrome, with significant improvements in cognition and behavior observed over two years, contrasting with minimal changes in standard care [1][2][3] - In open-label extension studies, 95% of patients reported improvements in overall clinical status after three years of treatment with zorevunersen [1][2] Company Overview - Biogen Inc. and Stoke Therapeutics are collaborating on the development of zorevunersen, an investigational antisense oligonucleotide aimed at treating Dravet syndrome by increasing functional NaV1.1 protein production [8][9] - Zorevunersen has received orphan drug designation from the FDA and EMA, as well as Breakthrough Therapy Designation for specific mutations in the SCN1A gene [8] Clinical Data - The ongoing open-label extension studies indicate long-term benefits of zorevunersen on seizures, cognition, and behavior, supporting its potential for disease modification [3][4] - Safety data from the studies show that zorevunersen is generally well tolerated, with treatment-emergent adverse events (TEAEs) reported in 30% of patients in Phase 1/2a studies and 53% in open-label extension studies [4] Disease Context - Dravet syndrome is characterized by severe seizures and significant cognitive and behavioral impairments, with over 90% of patients experiencing seizures despite the best available treatments [7] - The estimated prevalence of Dravet syndrome in the U.S. is around 16,000 patients, with no approved disease-modifying therapies currently available [7][17]

Core Viewpoint - The recent licensing agreement between Nuo Cheng Jian Hua and Zenas has led to a significant market reaction, with Nuo Cheng Jian Hua's stock dropping while Zenas's stock surged, indicating a divergence in market sentiment regarding the deal's value and potential [1][2]. Summary by Sections Licensing Agreement Details - Nuo Cheng Jian Hua has licensed its BTK inhibitor, Oubutini, for multiple sclerosis and other autoimmune diseases to Zenas, receiving an upfront payment of $100 million, milestone payments, and 7 million shares of Zenas stock, with a total potential deal value exceeding $2 billion [1][2]. - The upfront payment and stock value combined amount to $280 million, which is considered reasonable compared to industry standards, where the average upfront payment ratio is around 8% [3]. Market Reaction and Sentiment - The market's cautious sentiment towards the deal stems from two main concerns: the upfront payment not meeting expectations and the perceived lack of recognition of Zenas as a partner [2][5]. - Nuo Cheng Jian Hua's stock fell by 6.24% in A-shares and 11.64% in Hong Kong shares, while Zenas's stock rose by 24.22% following the announcement [1]. Strategic Considerations - Nuo Cheng Jian Hua had previously engaged with multinational corporations (MNCs) but ultimately chose Zenas due to smoother communication and Zenas's strong clinical development capabilities, particularly in the field of multiple sclerosis [5][10]. - Zenas, founded in 2019 and listed on NASDAQ in 2024, currently has no commercial products but has a promising pipeline, including a dual-function monoclonal antibody that complements Oubutini [7][8]. Industry Context - The collaboration reflects a shift in the global innovation drug landscape from one-time licensing deals to deeper collaborative models, where local pharmaceutical companies can retain equity in new ventures [12]. - Nuo Cheng Jian Hua's previous partnership with Biogen ended after about 18 months, highlighting the challenges in securing long-term collaborations in the industry [11]. Future Outlook - The partnership aims to advance the development of Oubutini in treating primary and secondary progressive multiple sclerosis, with significant market opportunities projected in the U.S. alone [8]. - The success of this collaboration will depend on Zenas's ability to progress its pipeline and the overall market performance of its shares [12].

Core Insights - Allka Research has over two decades of experience in investment, focusing on identifying undervalued assets in ETFs, commodities, technology, and pharmaceutical sectors [1] - The company emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [1] - Allka Research is committed to simplifying investment strategies, making them accessible to both seasoned and novice investors [1] - The mission of Allka Research includes sharing knowledge and analyses through Seeking Alpha, fostering a community of informed investors [1] Company Overview - Allka Research is dedicated to empowering individuals financially and aims to demystify the complexities of investing [1] - The company seeks to inspire confidence in its readers, enabling them to navigate the financial markets intelligently [1] - Allka Research's contributions to the Seeking Alpha community are focused on providing thought-provoking analyses and informed perspectives [1]

Core Insights - CervoMed Inc. has appointed Matthew Winton, Ph.D., as Chief Commercial and Business Officer to enhance its executive leadership team as it prepares for late-stage development and market readiness [1][2] - Dr. Winton brings nearly two decades of experience in the biotechnology industry, with a focus on commercializing treatments in the central nervous system (CNS) space [1][2] Company Developments - The appointment of Dr. Winton is seen as pivotal as CervoMed advances into late-stage Phase 3 development of neflamapimod, aimed at treating dementia with Lewy bodies (DLB) [2] - Dr. Winton's previous roles include Chief Operating Officer at Inozyme Pharma and senior leadership positions at Biogen, where he managed multi-billion-dollar neurology portfolios [2][3] Product Focus - CervoMed is developing neflamapimod, an investigational orally administered small molecule that targets synaptic dysfunction associated with neurodegenerative diseases like DLB [5] - The company recently completed a Phase 2b trial for neflamapimod, indicating progress in its clinical development [5] Inducement Grants - On October 6, 2025, CervoMed granted Dr. Winton an option to purchase 75,000 shares of common stock at an exercise price of $8.62, with vesting over three years [4]

Core Insights - BioArctic AB's partner Eisai has launched lecanemab-irmb (Leqembi Iqlik) as a subcutaneous injection for maintenance treatment of Alzheimer's disease in the U.S. after an initial 18-month intravenous treatment [1][7] - Leqembi is the first anti-amyloid treatment that allows at-home injections, enhancing patient convenience and potentially reducing healthcare resource utilization [3][7] - The Leqembi Companion program has been introduced to support patients throughout their treatment journey, providing resources for insurance, financial support, and injection education [1][2] Company Overview - BioArctic AB is a Swedish biopharma company focused on innovative treatments for neurodegenerative diseases, including Alzheimer's disease [10] - The company has a long-standing collaboration with Eisai, which is responsible for the clinical development and commercialization of Leqembi globally [4][9] - BioArctic retains commercialization rights for Leqembi in the Nordic region and has no development costs associated with the drug [9] Product Details - Lecanemab targets both amyloid plaque and protofibrils, which are implicated in the neurodegeneration process of Alzheimer's disease [2][6] - The treatment is approved in 50 countries, including the U.S., Japan, China, and the EU, with ongoing regulatory reviews in 8 additional countries [7] - The Leqembi Iqlik device allows patients to self-administer the treatment at home, which may streamline the overall treatment pathway for Alzheimer's disease [3][7] Clinical Studies - Eisai's Phase 3 clinical study (AHEAD 3-45) is ongoing, focusing on individuals with preclinical Alzheimer's disease, and aims to further evaluate the efficacy of lecanemab [8] - The Tau NexGen clinical study for Dominantly Inherited Alzheimer's Disease (DIAD) is also ongoing, incorporating lecanemab as a key treatment component [8]